Patents-Review.com
🔗 Permalink
Assignee profile:

Oryzon Genomics, S.A.

City:

Madrid

Country:

Spain

Published Applications:

17

Last publication date:

2026-06-04

Patent Grants:

13

Last grant date:

2026-06-30

Top Inventors for applications by Oryzon Genomics, S.A.

These are the the leading inventors for applications assigned to Oryzon Genomics, S.A.:

Recent patent applications by Oryzon Genomics, S.A.

Oryzon Genomics, S.A. based in Madrid, ES has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2026-06-04
US20260151399A1
Human necessities

COMBINATIONS OF LSD1 INHIBITORS AND MENIN INHIBITORS FOR TREATING CANCER

 #2 | 2025-09-25
US20250295660A1
Human necessities

METHODS OF TREATING NF1-MUTANT TUMORS USING LSD1 INHIBITORS

 #3 | 2025-09-04
US20250275969A1
Human necessities

METHODS OF TREATING MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) USING LSD1 INHIBITORS

 #4 | 2023-01-26 ✅ Patent 12,668,591 granted on 2026-06-30
US20230026909A1
Chemistry; metallurgy

1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS

 #5 | 2022-12-08 ✅ Patent 12,195,783 granted on 2025-01-14
US20220389478A1
Chemistry; metallurgy

Methods to determine KDM1A target engagement and chemoprobes useful therefor

 #6 | 2022-12-01 ✅ Patent 12,564,559 granted on 2026-03-03
US20220378722A1
Human necessities

COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS

 #7 | 2022-05-19 ✅ Patent 12,673,044 granted on 2026-07-07
US20220151998A1
Human necessities

METHODS OF TREATING BORDERLINE PERSONALITY DISORDER

 #8 | 2021-07-29
US20210228490A1
Human necessities

STABLE PHARMACEUTICAL FORMULATION

 #9 | 2019-03-21 ✅ Patent 11,034,991 granted on 2021-06-15
US20190085372A1
Chemistry; metallurgy

Methods to determine KDM1A target engagement and chemoprobes useful therefor

 #10 | 2019-03-21 ✅ Patent 10,780,081 granted on 2020-09-22
US20190083469A1
Human necessities

Method of treating multiple sclerosis employing a LSD1-inhibitor

 #11 | 2019-03-21 ✅ Patent 11,013,698 granted on 2021-05-25
US20190083417A1
Human necessities

Combinations of LSD1 inhibitors for the treatment of hematological malignancies

 #12 | 2018-12-13 ✅ Patent 10,329,256 granted on 2019-06-25
US20180354902A1
Chemistry; metallurgy

(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors

 #13 | 2018-05-10 ✅ Patent 10,233,178 granted on 2019-03-19
US20180127406A1
Chemistry; metallurgy

Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use

 #14 | 2018-03-29 ✅ Patent 10,221,125 granted on 2019-03-05
US20180086692A1
Chemistry; metallurgy

Solid forms

 #15 | 2018-03-22 ✅ Patent 10,214,477 granted on 2019-02-26
US20180079709A1
Chemistry; metallurgy

(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors

 #16 | 2017-10-05 ✅ Patent 10,265,279 granted on 2019-04-23
US20170281567A1
Human necessities

Combinations of LSD1 inhibitors for use in the treatment of solid tumors

 #17 | 2015-12-24 ✅ Patent 10,202,330 granted on 2019-02-12
US20150368186A1
Chemistry; metallurgy

Lysine specific demethylase-1 inhibitors and their use

Also check out Oryzon Genomics, S.A.'s (Madrid, Spain) applicant profile with 18 patent applications submitted.

AssigneeID:

313216 ⎘